×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DERM – journey medical corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DERM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/1
04:01 pm
derm
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
Low
Report
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
3/28
08:03 am
derm
Journey Medical Co. (NASDAQ: DERM) had its "buy" rating re-affirmed by analysts at Alliance Global Partners.
Low
Report
Journey Medical Co. (NASDAQ: DERM) had its "buy" rating re-affirmed by analysts at Alliance Global Partners.
3/26
04:01 pm
derm
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
Medium
Report
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
3/24
08:30 am
derm
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
High
Report
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
3/19
04:01 pm
derm
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
Medium
Report
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
3/12
08:30 am
derm
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
Low
Report
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
3/5
04:01 pm
derm
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
Medium
Report
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
3/4
06:13 pm
derm
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida [Yahoo! Finance]
Medium
Report
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:01 pm
derm
journey medical corporation
BEAT
Report
-6.1%
journey medical corporation
8/12/2024
04:01 pm
derm
journey medical corporation
BEAT
Report
14.2%
journey medical corporation
5/13/2024
04:00 pm
derm
journey medical corporation
BEAT
Report
1.1%
journey medical corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/27
06:01 am
derm
Form 10-K Journey Medical Corp For: Dec 31
Low
Report
Form 10-K Journey Medical Corp For: Dec 31
3/26
04:07 pm
derm
Form 8-K Journey Medical Corp For: Mar 26
Medium
Report
Form 8-K Journey Medical Corp For: Mar 26
3/24
08:30 am
derm
Form 8-K Journey Medical Corp For: Mar 24
High
Report
Form 8-K Journey Medical Corp For: Mar 24
3/11
07:53 pm
derm
Form 4 Journey Medical Corp For: Mar 11 Filed by: Maraoui Claude
Medium
Report
Form 4 Journey Medical Corp For: Mar 11 Filed by: Maraoui Claude
3/10
06:22 pm
derm
Form 4 Journey Medical Corp For: Mar 06 Filed by: Maraoui Claude
Medium
Report
Form 4 Journey Medical Corp For: Mar 06 Filed by: Maraoui Claude
3/5
07:53 pm
derm
Form 4 Journey Medical Corp For: Mar 03 Filed by: Maraoui Claude
Low
Report
Form 4 Journey Medical Corp For: Mar 03 Filed by: Maraoui Claude
2/24
04:01 pm
derm
Form 4 Journey Medical Corp For: Feb 21 Filed by: Benesch Joseph
Low
Report
Form 4 Journey Medical Corp For: Feb 21 Filed by: Benesch Joseph
2/5
04:02 pm
derm
Form 8-K Journey Medical Corp For: Feb 05
Medium
Report
Form 8-K Journey Medical Corp For: Feb 05
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/17
Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference
25.8%
12/10 Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 15.2%
5/7 Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 12.0%
12/12 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 10.6%
8/7 Q2/2019 6/30/2019 EPS -0.330 ZacksConsensus -0.900 ActVsEst 0.570 - Beat 10.6%
6/6 Form 4 Dermira, Inc. For: Jun 04 Filed by: Cohen David E 7.3%
12/10 Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis 7.2%
6/14 Form 4 Dermira, Inc. For: Jun 12 Filed by: Nunn Jason Raleigh 5.1%
8/17 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.1%
1/3 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.1%
12/10 Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 15.2%
5/7 Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 12.0%
12/12 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 10.6%
8/7 Q2/2019 6/30/2019 EPS -0.330 ZacksConsensus -0.900 ActVsEst 0.570 - Beat 10.6%
6/6 Form 4 Dermira, Inc. For: Jun 04 Filed by: Cohen David E 7.3%
12/10 Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis 7.2%
6/14 Form 4 Dermira, Inc. For: Jun 12 Filed by: Nunn Jason Raleigh 5.1%
8/17 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.1%
1/3 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.1%
TOP News Decliners
11/5
Form 10-Q Dermira, Inc. For: Sep 30
-9.1%
11/13 Dermira Elects Halley E. Gilbert to its Board of Directors -6.9%
6/10 Form 8-K Dermira, Inc. For: Jun 04 -6.1%
11/5 Dermira Inc (NASDAQ: DERM) had its "outperform" rating re-affirmed by analysts at Leerink Swann. They now have a $15.00 price target on the stock, down previously from $23.00. -5.6%
5/8 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
10/12 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.2%
8/7 Form 8-K Dermira, Inc. For: Aug 07 -5.0%
5/14 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.5%
8/9 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -4.4%
10/9 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis -4.1%
11/13 Dermira Elects Halley E. Gilbert to its Board of Directors -6.9%
6/10 Form 8-K Dermira, Inc. For: Jun 04 -6.1%
11/5 Dermira Inc (NASDAQ: DERM) had its "outperform" rating re-affirmed by analysts at Leerink Swann. They now have a $15.00 price target on the stock, down previously from $23.00. -5.6%
5/8 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
10/12 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.2%
8/7 Form 8-K Dermira, Inc. For: Aug 07 -5.0%
5/14 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.5%
8/9 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -4.4%
10/9 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: